Physician profile
Katarzyna Lee
NPI 1689221863
$3,131.05
in general payments reported to CMS, 2019-2025
26 companies · $423 in 2025
The $423 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $534 · 2022: $751 · 2023: $635 · 2024: $789 · 2025: $423.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,847.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,846.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Forte Bio-Pharma LLC | $415.81 | 2021-2025 | Prolate, Nalocet, Tanlor |
| Collegium Pharmaceutical, INC. | $404.14 | 2021-2025 | Xtampza |
| Medtronic, INC. | $358.00 | 2021-2025 | Kyphon Express II Kyphopak Tray |
| Scilex Pharmaceuticals INC. | $310.81 | 2021-2025 | Ztlido |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $214.47 | 2022-2025 | Relistor |
| Abbvie INC. | $191.96 | 2021-2025 | |
| Ibsa Pharma INC. | $165.97 | 2023-2025 | Tirosint, Licart, Flector |
| Pfizer INC. | $149.99 | 2023-2024 | |
| Azurity Pharmaceuticals, INC. | $131.74 | 2023-2024 | Horizant, Horizant |
| Kowa Pharmaceuticals America, INC. | $112.37 | 2022-2023 | Seglentis |
| Arbor Pharmaceuticals, INC. | $103.05 | 2021-2022 | |
| Vertex Pharmaceuticals Incorporated | $80.09 | 2025 | |
| Biotronik Nro, INC. | $72.79 | 2024-2025 | Prospera |
| Horizon Therapeutics Plc | $70.17 | 2021-2022 | |
| Almatica Pharma LLC | $58.84 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $39.99 | 2023 | Vyepti |
| Allergan, INC. | $34.29 | 2021-2022 | |
| Valinor Pharma, LLC | $33.99 | 2023-2024 | Movantik |
| Biohaven Pharmaceuticals, INC. | $29.69 | 2021 | |
| Redhill Biopharma INC. | $28.75 | 2021 | |
| Depuy Synthes Sales INC. | $27.94 | 2022-2024 | Orthovisc, Monovisc |
| Biodelivery Sciences International, INC. | $26.21 | 2021 | |
| Nevro Corp. | $20.50 | 2021 | |
| Boston Scientific Corporation | $18.85 | 2024 | Varithena Administration Pack |
| Bioventus LLC | $17.30 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.34 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katarzyna Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.